宁泌泰胶囊治疗Ⅲ型前列腺炎的临床研究

Clinical study of Ningmitai capsule in the treatment of type Ⅲ prostatitis

目的:探讨宁泌泰胶囊治疗Ⅲ型前列腺炎的临床效果及安全性。方法:选择2014年1月至2015年2月在我院接受治疗的Ⅲ型前列腺炎200例,按随机数字表分为观察组和对照组,每组各100例,观察组口服宁泌泰胶囊,4粒/次,3次/d,疗程12周。对照组口服诺氟沙星,400mg/次,3次/d,连续治疗12周。以慢性前列腺症状指数(NIH-CPSI)、中医证候评分、前列腺按摩液(EPS)中白细胞计数为疗效指标,进行治疗前后治疗效果的比较。结果:两组患者治疗后疼痛症状、排尿症状、生活质量等评分均明显下降,差异有统计学意义(P<0.05),观察组患者治疗后NIH-CPSI评分明显优于对照组患者,差异有统计学意义(P<0.05);治疗后观察组白细胞测定结果明显优于对照组(P<0.05);两组患者治疗期间未观察到严重不良反应发生。结论:宁泌泰胶囊治疗Ⅲ型前列腺炎的临床效果确切,安全性高,能明显改善患者疼痛、排尿症状和生活质量。

Objectives： To investigate the clinical efficacy and safety of Ningmitai capsule in the treatment of type Ⅲ prostatitis. Methods： 200 patients with type Ⅲ prostatitis treated in our hospital from January 2014 to February 2015 were randomly divided into the observation group and control group,100 cases in each group. The observation group was given oral administration of Ningmitai capsule,4 capsules each time,3 times a day,for 12 weeks. The control group received oral administration of levofloxacin,400 mg each time,3 times a day,for 12 weeks. The treatment effect was compared based on index in the chronic prostate symptom index（ NIH- CPSI）,TCM syndrome score and prostatic fluid（ EPS）. Results： After treatment,the pain symptoms,urinary symptoms,quality of life and other scores were significantly decreased,with statistically significant difference（ P〈0. 05） in both groups. The NIH- CP- SI score in the observation group was significantly better than that in the control group,with statistically significant difference（ P〈0. 05）. After treatment,the leucocyte test results of observation group were significantly better than that of control group（ P〈0. 05）. No serious adverse reactions occurred during the treatment of the two groups. Conclusion： Ningmitai capsule is safe and effective in the treatment of type Ⅲprostatitis,which can relieve the patients＇ pain and voiding symptoms and improve their quality of life.